Press Release Headlines

Human Mers-CoV Specimens in Florida and Indiana Found to Contain Identical Replikins Gene Sequences to Replikins of Other Countries

Global Target Established: Replikins Identical in Humans and Camels; Anti-Mers-CoV Replikins Vaccine™ Available and Testing Has Started

LONDON, May 19, 2014 /PRNewswire/ — In an analysis of the human specimen gene sequences published Saturday, May 17 by PubMed, Bioradar UK, Ltd. found the Replikin gene sequences of the human Mers-CoV specimens in Florida and Indiana to contain identical Replikin gene sequences to those from other countries. These new findings followed BioRadar news released Friday, May 16 showing that the Replikins of Mers-CoV virus were identical in both humans and in camels, conserved from 2012 to the present in all countries where outbreaks and sequences have been reported.

This new Replikin analysis of Saturday's PubMed data, which shows Mers gene sequences from cases in the U.S., validates that the clearly defined target of the solid-phase-synthetic-vaccine manufactured by Replikins, Ltd. is correct and currently global. It has led to the beginning of animal studies. If safety and efficacy requirements are met, the Anti-Mers-CoV Replikins Vaccine ™ can be ready for human trials in as soon as eight weeks.

It is hoped that these actions will lead to a prototype for interrupting outbreaks before they become pandemics.

From Friday's Bioradar report:

Identical Shared Replikins Found in Genes of Mers-CoV Virus Infecting Camels and Humans, Conserved from 2012 to 2014.

London. May 16, 2014.  

The Replikins Synthetic Anti-Mers Vaccine is unique because:

  1. Prediction: The vaccine is based on the same gene technology which correctly predicts, one to two years in advance, the coming breakthrough or pandemic, as established retrospectively one year before the Sars outbreak of 2003; and prospectively i) in June 2013 for the current Mers outbreaks; ii) in 2006 for the 2007 H5N1 lethal outbreak in Indonesia; iii) in 2010-2011 for the H5N1 outbreaks in Cambodia; and iv) in 2008 for the 2009 H1N1 pandemic. (4)
  2. The concentration of gene Replikins (Replikin Count=Number of Replikins per 100 amino acids) relates quantitatively to rapid replication of the pathogen, and to morbidity and mortality, whether the pathogen is a virus, bacterium, or cancer cell.
  3. The prediction identifies the specific gene Replikin structures involved in the rapid replication and outbreaks of the attacking pathogen.
  4. The prediction also defines the geographic areas which have the highest pathogen Replikins activity, from which global spread initiates, and to which public health and vaccine containment efforts can be directed (as with Indonesia for H5N1 in 2006, and Saudi Arabia for the current Mers outbreaks)(4).
  5. The specific gene Replikin structures identified are the basis of the synthetic vaccine designed;
  6. Such Replikin vaccines have been produced freeze-dried by solid phase synthesis in 7 days, can be produced in unlimited quantities before the outbreak peaks, have been shipped without need of refrigeration, and have been found effective against Taura Syndrome virus in shrimp and influenza H5N1 virus in chickens (4).
  7. The discovery of identical Mers gene Replikins structures in both infected humans and in camels provides a defined parallel host relationship for vaccine testing. It would be useful to determine if the vaccine would increase immunity and decrease clinical outbreaks in camels. If sufficiently safe and effective in camels by classical criteria, extension of the trials to humans may be considered.

Replikins therefore, provide a complete defense system, not previously available, beginning with prediction pre-outbreak, based on detection and specific identification of the quantitative gene changes associated with rapid replication. These gene changes can be addressed in advance of, or after, outbreaks occur, providing time to possibly prevent pandemics rather than just to react to them.

While it would have been preferable to begin testing the Replikins vaccine when the upturn in gene Replikin Count was noted in October 2013 (1), there still may be time to reduce or interrupt the present progression of Mers-CoV.

Contact: Email, Tel 646-320-5910

1.MERS WATCH BBC October 21, 2013
2.CIDRAP NEWS. Reports: Mers-CoV found in Saudi's patient's camel.Nov. 11, 2013.
3.Memish,Ziad. Promed Mail. Animal reservoirs, camels. Nov. 12, 2013.
4.Bogoch S and Bogoch ES. Nature Precedings doi: 10.1038/npre.2012.6952.1  Replikins Pandemic Prevention: Increase of Strain-Specific Influenza Genomic Replikin Counts, Having Predicted Outbreaks and their Location Seven Times Consecutively, Up to Two Years in Advance, Provides Time for Prevention of Pandemics.
5.Replikins Reports < Replikins > 2006-2014.